来自Astragali Radix的不同分子重量的多糖的结构性表征和抗炎活性查
Xinhui Fan1,2,3, Ke Li1,2,4, Xuemei Qin1,2
1Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, China.
Chemistry & biodiversity
|May 5, 2024
概括
阿斯特拉加利雷迪克斯多糖 (Astragali Radix polysaccharides,简称APSs) 显示出免疫调节和抗炎作用. 这项研究描述了APS分数,确定了负责抗炎活性的特定寡糖,指导了未来的药物开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 自然产品 化学 化学
背景情况:
- 阿斯特拉加利雷迪克斯多糖 (Astragali Radix polysaccharides,简称APSs) 已知具有免疫调节作用,但它们的抗炎机制需要详细的结构分析.
- 有限的研究存在于具有不同分子量 (MW) 的APS的结构-活性关系及其抗炎潜力.
- 研究不同的APS分数对于理解它们的特定生物活动和治疗应用至关重要.
研究的目的:
- 系统地分析Astragali Radix多糖化物 (APSs) 分的结构.
- 使用脂多糖 (LPS) 诱导的RAW264.7巨模型选和比较不同APS分量的抗炎活性.
- 阐明负责观察到的抗炎作用的特定寡糖结构.
主要方法:
- 利用脂聚糖 (LPS) 诱导的 RAW264.7 巨细胞来评估 APS 分数的抗炎活性.
- 采用三酸 (TFA) 水解和甲基化用于寡糖衍生物化.
- 用MALDI-TOF-MS和UPLC-Q-Exactive-MS/MS进行结构阐明,分析了衍生型寡糖.
主要成果:
- 与APS-II相比,APS-I部分表现出更强的抗炎作用.
- 鉴定出APS-I是一种富含葡萄糖 (46.8%) 和银河糖 (34.4%) 的 hetero-polysaccharide (MW ~2.0×10^6 Da).
- 降解产品,阿斯特拉加利基根寡糖化物 (APOS),具有2-16的聚合度,并被描述为1,4-葡萄糖寡糖化物和1,4-银寡糖化物.
结论:
- 阿斯特拉加利雷迪克斯多糖 (Astragali Radix polysaccharides,简称APSs) 具有显著的抗炎性质,其中APS-I分量特别有效.
- 该研究确定了特定的1,4-glucooligosaccharides和1,4-galactooligosaccharides作为促进抗炎活性的关键成分.
- 这些发现为了解APS结构功能关系和开发新型抗炎药物提供了基础.
相关概念视频
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...


